148 related articles for article (PubMed ID: 10831180)
1. Improvement by the insulin-sensitizing agent, troglitazone, of abnormal fibrinolysis in type 2 diabetes mellitus.
Kato K; Yamada D; Midorikawa S; Sato W; Watanabe T
Metabolism; 2000 May; 49(5):662-5. PubMed ID: 10831180
[TBL] [Abstract][Full Text] [Related]
2. Effects of troglitazone on blood concentrations of plasminogen activator inhibitor 1 in patients with type 2 diabetes and in lean and obese normal subjects.
Kruszynska YT; Yu JG; Olefsky JM; Sobel BE
Diabetes; 2000 Apr; 49(4):633-9. PubMed ID: 10871202
[TBL] [Abstract][Full Text] [Related]
3. Effect of troglitazone on fibrinolysis and activated coagulation in patients with non-insulin-dependent diabetes mellitus.
Fonseca VA; Reynolds T; Hemphill D; Randolph C; Wall J; Valiquet TR; Graveline J; Fink LM
J Diabetes Complications; 1998; 12(4):181-6. PubMed ID: 9647334
[TBL] [Abstract][Full Text] [Related]
4. Differential effects of metformin and troglitazone on cardiovascular risk factors in patients with type 2 diabetes.
Chu NV; Kong AP; Kim DD; Armstrong D; Baxi S; Deutsch R; Caulfield M; Mudaliar SR; Reitz R; Henry RR; Reaven PD
Diabetes Care; 2002 Mar; 25(3):542-9. PubMed ID: 11874944
[TBL] [Abstract][Full Text] [Related]
5. Further insight on the hypoglycemic and nonhypoglycemic effects of troglitazone 400 or 600 mg/d: effects on the very-low-density and high-density lipoprotein particle distribution.
Gómez-Pérez FJ; Aguilar-Salinas CA; Vázquez-Chávez C; Fanghänel-Salmón G; Gallegos-Martínez J; Gómez-Diaz RA; Salinas-Orozco S; Chavira-López IJ; Sánchez-Reyes L; Torres-Acosta EM; Tamez R; López A; Guillén LE; Cesarman G
Metabolism; 2002 Jan; 51(1):44-51. PubMed ID: 11782871
[TBL] [Abstract][Full Text] [Related]
6. Troglitazone improves defects in insulin action, insulin secretion, ovarian steroidogenesis, and fibrinolysis in women with polycystic ovary syndrome.
Ehrmann DA; Schneider DJ; Sobel BE; Cavaghan MK; Imperial J; Rosenfield RL; Polonsky KS
J Clin Endocrinol Metab; 1997 Jul; 82(7):2108-16. PubMed ID: 9215280
[TBL] [Abstract][Full Text] [Related]
7. Serum leptin level as an indicator to predict the clinical efficacy of troglitazone in patients with type 2 diabetes mellitus.
Maruyama S; Yanagisawa K; Kanamuro R; Teno S; Iwamoto Y
Diabetes Res Clin Pract; 2001 Sep; 53(3):161-4. PubMed ID: 11483231
[TBL] [Abstract][Full Text] [Related]
8. Effects of troglitazone on insulin action and cardiovascular risk factors in patients with non-insulin-dependent diabetes.
Sironi AM; Vichi S; Gastaldelli A; Pecori N; Anichini R; Foot E; Seghieri G; Ferrannini E
Clin Pharmacol Ther; 1997 Aug; 62(2):194-202. PubMed ID: 9284856
[TBL] [Abstract][Full Text] [Related]
9. Troglitazone, an insulin action enhancer, improves metabolic control in NIDDM patients. Troglitazone Study Group.
Kumar S; Boulton AJ; Beck-Nielsen H; Berthezene F; Muggeo M; Persson B; Spinas GA; Donoghue S; Lettis S; Stewart-Long P
Diabetologia; 1996 Jun; 39(6):701-9. PubMed ID: 8781766
[TBL] [Abstract][Full Text] [Related]
10. Effects of troglitazone: a new hypoglycemic agent in patients with NIDDM poorly controlled by diet therapy.
Iwamoto Y; Kosaka K; Kuzuya T; Akanuma Y; Shigeta Y; Kaneko T
Diabetes Care; 1996 Feb; 19(2):151-6. PubMed ID: 8718436
[TBL] [Abstract][Full Text] [Related]
11. Troglitazone reduces plasma levels of tumour necrosis factor-alpha in obese patients with type 2 diabetes.
Katsuki A; Sumida Y; Murata K; Furuta M; Araki-Sasaki R; Tsuchihashi K; Hori Y; Yano Y; Gabazza EC; Adachi Y
Diabetes Obes Metab; 2000 Jun; 2(3):189-91. PubMed ID: 11220554
[TBL] [Abstract][Full Text] [Related]
12. Effect of troglitazone in insulin-treated patients with type II diabetes mellitus. Troglitazone and Exogenous Insulin Study Group.
Schwartz S; Raskin P; Fonseca V; Graveline JF
N Engl J Med; 1998 Mar; 338(13):861-6. PubMed ID: 9516220
[TBL] [Abstract][Full Text] [Related]
13. Troglitazone use in insulin-treated type 2 diabetic patients. The Troglitazone Insulin Study Group.
Buse JB; Gumbiner B; Mathias NP; Nelson DM; Faja BW; Whitcomb RW
Diabetes Care; 1998 Sep; 21(9):1455-61. PubMed ID: 9727891
[TBL] [Abstract][Full Text] [Related]
14. Effect of troglitazone in type 2 diabetes mellitus.
Gorson DM
N Engl J Med; 1998 Aug; 339(6):406. PubMed ID: 9696655
[No Abstract] [Full Text] [Related]
15. Effect of troglitazone in type 2 diabetes mellitus.
Rusk MH
N Engl J Med; 1998 Aug; 339(6):406. PubMed ID: 9696656
[No Abstract] [Full Text] [Related]
16. A comparison of troglitazone and metformin on insulin requirements in euglycemic intensively insulin-treated type 2 diabetic patients.
Yu JG; Kruszynska YT; Mulford MI; Olefsky JM
Diabetes; 1999 Dec; 48(12):2414-21. PubMed ID: 10580431
[TBL] [Abstract][Full Text] [Related]
17. Troglitazone monotherapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized, controlled study. The Troglitazone Study Group.
Fonseca VA; Valiquett TR; Huang SM; Ghazzi MN; Whitcomb RW
J Clin Endocrinol Metab; 1998 Sep; 83(9):3169-76. PubMed ID: 9745421
[TBL] [Abstract][Full Text] [Related]
18. The effect of a thiazolidinedione drug, troglitazone, on glycemia in patients with type 2 diabetes mellitus poorly controlled with sulfonylurea and metformin. A multicenter, randomized, double-blind, placebo-controlled trial.
Yale JF; Valiquett TR; Ghazzi MN; Owens-Grillo JK; Whitcomb RW; Foyt HL
Ann Intern Med; 2001 May; 134(9 Pt 1):737-45. PubMed ID: 11329231
[TBL] [Abstract][Full Text] [Related]
19. Deterioration of glycemic control after long-term treatment with troglitazone in nonobese type 2 diabetic patients.
Murase Y; Wakasugi T; Yagi K; Mabuchi H
Diabetes Care; 2000 Jan; 23(1):131-2. PubMed ID: 10857989
[No Abstract] [Full Text] [Related]
20. Troglitazone decreases serum uric acid concentrations in type II diabetic patients and non-diabetics.
Iwatani M; Wasada T; Katsumori K; Watanabe-Takahashi C; Kamatani N; Iwamoto Y
Diabetologia; 2000 Jun; 43(6):814-5. PubMed ID: 10907128
[No Abstract] [Full Text] [Related]
[Next] [New Search]